New Psychedelic Drug Derivative Secures Patent and Awaits FDA Approval

Doubleblind Enveric Biosciences dubs EB-002 as a “next-generation” psilocin pro-drug and aims to use it as a stepping stone for its future, trip-free psychedelic medications. veryone is watching MAPS and Lykos Therapeutics to see whether the FDA will approve MDMA-assisted therapy for PTSD, and if Lykos will secure a patent for MDMA. But while all the attention has […]